Danilo Rocco, Ciro Battiloro, Luigi Della Gravara and Cesare Gridelli* Pages 120 - 128 ( 9 )
Background: Lung cancer is the leading cause of cancer mortality, being responsible for more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers; moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations, being suitable for EGFR-Tyrosine Kinase Inhibitors (TKI) molecular targeted therapy. However, EGFR+ NSCLCs gain acquired resistance to these agents, representing one of the key challenges for modern precision oncology.
Objective: Therefore, this paper aims to provide an extensive state of the art review, alongside with hints about future perspectives.
Conclusion: To date, in the light of the data from the FLAURA study, osimertinib represents the best first-line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational.
Combination therapy, EGFR, NSCLC, Osimertinib, T790M, TKI.
Division of Pulmonary Oncology, Azienda Ospedaliera Dei Colli Monaldi, Naples, Division of Pulmonary Oncology, Azienda Ospedaliera Dei Colli Monaldi, Naples, Luigi Vanvitelli University, Caserta, Division of Medical Oncology, AORN Giuseppe Moscati, Avellino